These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 38504082)

  • 1. Population Pharmacodynamic Dose-Response Analysis of Serum Potassium Following Dosing with Sodium Zirconium Cyclosilicate.
    Penland RC; Åstrand M; Boulton DW; Någård M
    Clin Pharmacokinet; 2024 Apr; 63(4):551-560. PubMed ID: 38504082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correction of serum potassium with sodium zirconium cyclosilicate in Japanese patients with hyperkalemia: a randomized, dose-response, phase 2/3 study.
    Kashihara N; Nishio T; Osonoi T; Saka Y; Imasawa T; Ohtake T; Mizuno H; Shibagaki Y; Kim H; Yajima T; Sarai N
    Clin Exp Nephrol; 2020 Dec; 24(12):1144-1153. PubMed ID: 32779057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emergency Potassium Normalization Treatment Including Sodium Zirconium Cyclosilicate: A Phase II, Randomized, Double-blind, Placebo-controlled Study (ENERGIZE).
    Peacock WF; Rafique Z; Vishnevskiy K; Michelson E; Vishneva E; Zvereva T; Nahra R; Li D; Miller J
    Acad Emerg Med; 2020 Jun; 27(6):475-486. PubMed ID: 32149451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia: A 12-Month Phase 3 Study.
    Spinowitz BS; Fishbane S; Pergola PE; Roger SD; Lerma EV; Butler J; von Haehling S; Adler SH; Zhao J; Singh B; Lavin PT; McCullough PA; Kosiborod M; Packham DK;
    Clin J Am Soc Nephrol; 2019 Jun; 14(6):798-809. PubMed ID: 31110051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sodium zirconium cyclosilicate increases serum bicarbonate concentrations among patients with hyperkalaemia: exploratory analyses from three randomized, multi-dose, placebo-controlled trials.
    Roger SD; Spinowitz BS; Lerma EV; Fishbane S; Ash SR; Martins JG; Quinn CM; Packham DK
    Nephrol Dial Transplant; 2021 Apr; 36(5):871-883. PubMed ID: 32588050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potassium responses to sodium zirconium cyclosilicate in hyperkalemic hemodialysis patients: post-hoc analysis of DIALIZE.
    Fishbane S; Ford M; Fukagawa M; McCafferty K; Rastogi A; Spinowitz B; Staroselskiy K; Vishnevskiy K; Lisovskaja V; Al-Shurbaji A; Guzman N; Bhandari S
    BMC Nephrol; 2022 Feb; 23(1):59. PubMed ID: 35135481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects and Safety of a Novel Oral Potassium-Lowering Drug-Sodium Zirconium Cyclosilicate for the Treatment of Hyperkalemia: a Systematic Review and Meta-Analysis.
    Zhang Y; Xu R; Wang F; Liu Y; Xu J; Zhao N; Cheng F; Long L; Jia J; Lin S
    Cardiovasc Drugs Ther; 2021 Oct; 35(5):1057-1066. PubMed ID: 33459923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Sodium Zirconium Cyclosilicate for Treatment of Hyperkalemia: An 11-Month Open-Label Extension of HARMONIZE.
    Roger SD; Spinowitz BS; Lerma EV; Singh B; Packham DK; Al-Shurbaji A; Kosiborod M
    Am J Nephrol; 2019; 50(6):473-480. PubMed ID: 31658466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term safety and efficacy of sodium zirconium cyclosilicate for hyperkalaemia in patients with mild/moderate versus severe/end-stage chronic kidney disease: comparative results from an open-label, Phase 3 study.
    Roger SD; Lavin PT; Lerma EV; McCullough PA; Butler J; Spinowitz BS; von Haehling S; Kosiborod M; Zhao J; Fishbane S; Packham DK
    Nephrol Dial Transplant; 2021 Jan; 36(1):137-150. PubMed ID: 32030422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum potassium response to single-dose sodium zirconium cyclosilicate for the treatment of asymptomatic hyperkalemia in hospitalized patients.
    Lewis H; Stamper B; Yungkurth AC
    Pharmacotherapy; 2024 Jan; 44(1):13-21. PubMed ID: 37475499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DIALIZE China: A Phase IIIb, Randomized, Placebo-Controlled Study to Reduce Predialysis Hyperkalemia With Sodium Zirconium Cyclosilicate in Chinese Patients.
    Ni Z; Lu R; Xu X; Bian X; Zhou Z; Yang J; Luo Q; Chen M; Chen C; Sun X; Yu L; He Q; Jiang H; Yuan W; Li Y; Zhou R; Wang J; Zhang X; Zuo L; Meng X; Chang Z; Zhao J; Wessman P; Xiang P;
    Clin Ther; 2023 Jul; 45(7):633-642. PubMed ID: 37385905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase 3 multicenter open-label maintenance study to investigate the long-term safety of sodium zirconium cyclosilicate in Japanese subjects with hyperkalemia.
    Kashihara N; Yamasaki Y; Osonoi T; Harada H; Shibagaki Y; Zhao J; Kim H; Yajima T; Sarai N
    Clin Exp Nephrol; 2021 Feb; 25(2):140-149. PubMed ID: 33098526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study of Sodium Zirconium Cyclosilicate for Reducing the Incidence of Predialysis Hyperkalemia.
    Fishbane S; Ford M; Fukagawa M; McCafferty K; Rastogi A; Spinowitz B; Staroselskiy K; Vishnevskiy K; Lisovskaja V; Al-Shurbaji A; Guzman N; Bhandari S
    J Am Soc Nephrol; 2019 Sep; 30(9):1723-1733. PubMed ID: 31201218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of sodium zirconium cyclosilicate for hyperkalaemia: the randomized, placebo-controlled HARMONIZE-Global study.
    Zannad F; Hsu BG; Maeda Y; Shin SK; Vishneva EM; Rensfeldt M; Eklund S; Zhao J
    ESC Heart Fail; 2020 Feb; 7(1):54-64. PubMed ID: 31944628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sodium Zirconium Cyclosilicate: A Review in Hyperkalaemia.
    Hoy SM
    Drugs; 2018 Oct; 78(15):1605-1613. PubMed ID: 30306338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of sodium zirconium cyclosilicate in patients with baseline serum potassium level ≥ 5.5 mmol/L: pooled analysis from two phase 3 trials.
    Amin AN; Menoyo J; Singh B; Kim CS
    BMC Nephrol; 2019 Dec; 20(1):440. PubMed ID: 31791288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I Study of the Pharmacodynamics and Safety of Sodium Zirconium Cyclosilicate in Healthy Chinese Adults.
    Cheung T; Sun F; Zhao J; Qin Y; Någård M
    Clin Pharmacol Drug Dev; 2022 Mar; 11(3):348-357. PubMed ID: 34997825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of sodium zirconium cyclosilicate on sodium and potassium excretion in healthy adults: a Phase 1 study.
    Någård M; Singh B; Boulton DW
    Clin Kidney J; 2021 Aug; 14(8):1924-1931. PubMed ID: 34345416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of hyperkalemia in chronic heart failure using sodium zirconium cyclosilicate.
    Oshima A; Imamura T; Narang N; Kinugawa K
    Clin Cardiol; 2021 Sep; 44(9):1272-1275. PubMed ID: 34263946
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.